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Summary We investigated the relation between Helix pomatia (HPA) staining of primary breast cancer and
the presence of axillary (AX) or internal mammary (IM) metastases, and evaluated its predictive value for AX
or IM metastases in comparison with the use of clinical variables. There was a significant association between
the HPA staining and AX or IM metastases. When HPA staining was regarded as an indicator of AX
metastases, a diagnostic accuracy of 72%, a sensitivity of 69% and a specificity of 75% were achieved. As an
indicator of IM metastases, these values were 64%, 76% and 62%, respectively. In predicting the presence of
AX metastases using a discriminant function with clinical AX status, location of tumour and tumour size,
diagnostic accuracy, sensitivity and specificity were 79%, 69% and 87%, respectively. In predicting the
presence of IM metastases using the discriminant function with clinical AX status and tumour size, these
values were 74%, 71% and 75%, respectively. Therefore, it was concluded that the HPA staining may be
useful, but it was equivalent with the discriminant function with clinical variables in prediction of AX or IM
metastases.
The axillary lymph node (AX) region is the principal site for
metastatic spread from carcinoma of the breast. The second
major site of regional metastases is the internal mammary
lymph node (IM) chain. It is well known that histologic
presence or absence of AX and/or IM is a crucial diagnostic
parameter for the prognosis of the breast cancer patients
(Veronesi et al., 1985; Noguchi et al., 1991). Since there is a
trend towards more conservative forms of breast surgery in
many centers, however, AX or IM status remains unknown
for most patients. For these reasons, there is a clear need for
the development of accurate prognostic indices which do not
involve AX and/or IM dissection.
Alterations in cell surface carbohydrates have been related
to metastatic potential of experimental tumours and cor-
related with high and low metastatic sublines (Altevogt et al.,
1983; Steck et al., 1983). Lectins are proteins from different
origins which bind to carbohydrate groups. Among these
proteins, Brooks et al. (1991) suggested that Helix pomatia
agglutinin (HPA) might provide valuable information in
breast cancer patients in whom AX dissection has not been
preformed, because there is a significant relationship between
the HPA staining and AX metastases (Leathem et al., 1984;
1985; Fenlon et al., 1987; Alam et al., 1990). To explore
further the relevance of HPA staining, we investigated the
relation between the HPA staining of primary breast cancer
and the presence of AX or IM metastases, and evaluated its
predictive value for AX or IM metastases in comparison with
those using clinical variables.
Patients and methods
A total of 98 patiens with invasive breast cancer participated
in this study. They underwent extended radical mastectomy
in a clinical trial at the Department of Surgery II, Kanazawa
University Hospital, from April 1978 to June 1987. Clinical
stages (TNM classification) (Union Internationale Contre le
Cancer, 1987) were Stage 1 for 14 patients, Stage 2 for 55
patients, and Stage 3 for 29 patients.
Postoperatively, lymph nodes were removed from the
resected specimens. The average total number of dissected
axillary lymph nodes per patients was 26 nodes, with a range
of 12-105. At least three sections were made of each lymph
node for histological examination with Hematoxylin and
Eosin staining. There were 53 patients with negative AX, 20
with one to three positive AX, and 25 with four or more
positive AX. IM were positive in 17 patients and negative in
81 patients.
The method for preparation of the paraffin sections for
HPA staining has been described elsewhere (Fukutomi et al.,
1989). Most cases were clearly either intensively positive or
completely negative. In a few cases we used the scoring
defined by Brooks et al. (1991). Finally cases were classified
as positive or negative staining.
Statistically, a comparison was made using the chi-square
test. In the univariate study, overall or disease-free survival
was studied by the Kaplan-Meier method (Kaplan & Meier,
1958), and a log-rank test was used to assess statistical
significance. In the multivariate study, Cox's regression test
was used to examine several parameters simultaneously, fol-
lowed by multiple regression analysis to determine which
variables are important for predicting AX or IM metastases.
From the coefficients of variables selected by a stepwise
forward selection method, we were able to construct the
following discriminant function. Discriminant score (Z) =
a. + a,X, +.
..... + apXp, (a.; constant; al, a2.ap: discrimin-
ant coefficient; XI, X2. Xp: explanatory variables). The
probability (P) of positive AX or IM was calculated by the
following logistic function: P = ez/(1 + ez) = 1/(1 + e-z), e =
2.718.- ). For predicting the AX or IM metastases, Z>0
(P>0.5) was regarded as positive AX or IM, and Z.0
(P<0.5) as negative AX or IM.
Results
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Forty-four (45%) of the 98 breast cancers were HPA-posi-
tive, and the remaining 54 (55%), HPA-negative. The posi-
tive rates of HPA staining were significantly higher as the
disease progressed, with 7% for Stage 1, 42% for Stage 2,
and 69% for Stage 3 (P<0.01). Moreover, HPA staining
was found to be significantly associated with tumour size
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Table I Incidence of HPA staining related to axillary and internal mammary lymph node metas-
tases
Internal mammary Axillary lymph node metastases
metastases 0 1-3 >3 Total
I P<0.01 I
(-) 20% (10/49) 44% (8/18) 93% i13/14) 38% (31/81)-j
P<10.05
T. ES P<0.005
(+) 75% (3/4) 100% (2/2) 73% (8/11) 76% (13/17)J
1 NS I
Total 25% (13/53) 50% (10/20) 84% (21/25) 45% (44/98)
t P<0.01
NS, not significant.
(data not shown), AX and IM metastases (Table I), but not
significantly associated with age, menopausal status and his-
tologic type.
To improve the assessment of AX and IM metastases,
discriminant functions were calculated from the clinical and
biological variables. As effective variables for discrimination
of AX metastases, clinical AX status, location of tumour,
tumour size and HPA staining were selected by stepwise
forward selection analysis, whereas age, clinical AX status,
tumour size and HPA staining were selected as effective
variables for discrimination of IM metastases. For predicting
AX metastases, the discriminant function with clinical vari-
ables alone was expressed as follows: Z = - 3.63496 +3.20409
XI + 1.41493X2 + 1.00822X3 and that with both clinical
variables and HPA staining was expressed as follows: Z =
-3.69001 +2.87268X, +1.46574X2 +0.682377X3 +1.61291
X4, where XI = clinical AX nodal status (0= NO,Nla; 1 =
Nlb,N2,N3); X2 = location of primary tumour (0= medio-
lateral; 1 = lateral); X3 = tumour size (1 = >2.0 cm; 2 = 2.1 -
5.0 cm; 3 = >5.1 cm); X4 = HPA staining (0 = negative; 1 =
positive). For predicting IM metastases, the discriminant
function with clinical variables alone was expressed as follows:
Z = -4.18966 +0.896486X, + 1.87908X3, and that with both
clinical variables and HPA staining was expressed as follows:
Z = -2.15353 + 1.51724X1 + 1.20072X4 -0.703795X6, where
X6 = age (0 <35 years; 1 = 36-50 years; 2 >51 years). The
distribution of discriminant score related to AX and IM
metastases are shown in Figure 1. In prediction of AX
metastases by discriminant function with clinical variables
alone, consequently, an accuracy of 79%, a sensitivity of
69%, and a specificity of 87% were achieved. In prediction of
IM metastases by discriminant function with clinical vari-
ables alone, these values were 74%, 71% and 75%, respec-
tively. When HPA staining was regarded as an indicator of
AX metastases, a diagnostic accuracy of 72%, a sensitivity of
69% and a specificity of 75% were achieved. When regarded
as an indicator of IM metastases, these values became 64%,
76% and 62%, respectively. These predictive values were
weakly but not significantly improved by both clinical vari-
ables and HPA staining as compared to CV alone (Table TI).
When all the prognostic variables were examined individ-
ually in the univariate study (Table III), tumour size, HPA
staining, AX and IM metastases were significant factors for
overall and disease-free survival. When all variables were
considered simultaneously in multivariate analysis (Table III)
to identify which variables conveyed unique prognostic in-
formation, only AX and IM metastases were significant fac-
tors for both overall and disease-free survival, while HPA
Table II Prediction ofaxillary and internal mammary lymph node involvement by HPA staining of
primary breast tumour and/or clinical variables
Predictive values
Accuracy Sensitivity Specificity Positive Negative
Prediction ofAX metastases
by CV alone 79% 69% 87% 82% 77%
by HPA staining 72% 69% 75% 70% 74%
by CV and HPA staining 80% 71% 87% 82% 78%
Prediction ofIM metastases
by CV alone 74% 71% 75% 38% 92%
by HPA staining 64% 76% 62% 30% 93%
by CV and HPA staining 76% 76% 75% 39% 94%
AX, axillary lymph node; IM, Internal mammary lymph node; CV, Clinical variables.
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Figure 1 Correlation ofdiscriminant score with axillary and internal mammary lymph node metastases. 0, presence ofmetastases;
0, absence of metastases; CV, clinical variables.1370 M. NOGUCH et al.
Table III Factors affecting overall and disease-free survival by univariate and
multivariate analysis
Overall Survival Disease-Free Survival
Variables Univariate Multivariate Univariate Multivariate
Age NS NS NS NS
Menopausal status NS NS NS NS
Tumour size <0.05 NS NS NS
Histological type NS NS NS NS
AX metastases <0.001 <0.001 <0.001 <0.001
IM metastases <0.001 <0.01 <0.001 <0.01
HPA staining <0.01 NS <0.01 NS
AX, Axillary lymph nodes; IM, Internal mammary lymph nodes; NS, not
significant.
staining did not appear to be significant independent prog-
nostic factor. This actually emphasised a significant associa-
tion between HPA staining and AX or IMN metastases.
Discussion
Not only the management of IM metastases (Veronesi &
Valagussa, 1981; Lacour et al., 1987; Meier et al., 1989), but
also that of AX metastases (Kinne, 1983; Fisher et al., 1985;
Yang et al., 1987) has been controversial in operable breast
cancer patients. As an unanimous principle, AX should be
dissected in clinically AX-positive patients. However, the
need for immediate AX dissection in clinically AX-negative
patients has been questioned (Cascinelli et al., 1987), because
immediate AX dissection did not show any superiority in
terms of survival compared to AX dissection performed only
when clinical AX metastases appeared in a randomised
clinical study (Fisher et al., 1985). The main reason for AX
dissection in clinically AX-negative patients is the staging of
breast cancer, but the chances that AX are involved is only
of the order of 20-25% in those patients (Noguchi et al.,
1991). On the other hand, it has also been reported that
information about the presence or absence of IM metastases
is important for estimating the prognosis of breast cancer
patients (Veronesi et al., 1985; Noguchi et al., 1991). Never-
theless, routine IM dissection has not been justified as a
staging procedure, because IM are involved only in 20% of
the patients with operable breast cancer. If AX and/or IM
metastases can be accurately estimated by biological para-
meters, then, dissection of AX and/or IM can be avoided in
some breast cancer patients.
Leathem et al. (1984, 1985, 1987) found that lectin from
the albumin gland of the Roman snail, Helix pomatia agglu-
tinin (HPA), which recognises N-acetyl-galactosaminyl resi-
dues, binds to a population of breast-cancer cells associated
with AX metastases. Other investigators (Fenlon et al., 1987;
Alam et al., 1990; Brooks & Leathem, 1991) also reported
that the presence of HPA binding correlated with AX metas-
tases, whereas it has also been reported (Fukutomi et al.,
1989; Galea et al., 1991) that HPA staining was not related
to AX metastases. To our knowledge, however, none has
investigated a relationship between HPA binding to primary
tumour and the presence of IM metastases. The precentage
of stainers (45%) and non-stainers (55%) are similar to the
study of Fukutomi et al. (1989) but not in agreement with
the one of Brooks et al. (1991), in which the incidence of
PHA staining is 80% and PHA sensitivity with regard to
lymph node status is 96%. The present study showed a
significant correlation between HPA staining and AX or IM
metastases. Expression of HPA binding site in breast cancer
tissue may reflect the ability of a tumour to invade and
metastasise. Brooks et al. (1991) suggested that HPA binding
might provide valuable information in breast cancer patients
in whom AX sampling has not been performed. In the
present study, the predictive value of AX or IM metastases
by HPA staining was equivalent with that by the discrim-
inant function with clinical variables. HPA staining may
provide an adjuvant to discriminant function with clinical
variables. The difference in technique and lectin source
between the works of Brooks et al. (1991) and our may have
some bearing on the significance of the HPA staining,
although the incidence of HPA staining (45%) was similar
with the incidence of AX metastases (46%) in this study.
Since it is troublesome for clinicians to calculate the dis-
criminant function for each patient, and one of the principal
factors included in the discriminant function was clinical
axillary status, however, the usefulness of the discriminant
function would be limited. HPA staining would be a more
realistic alternative in the clinical setting.
Nevertheless, either HPA staining or the discriminant func-
tion was shown to be inaccurate with an accuracy of less
than 80%. They are still far from satisfactory. In this study,
it was confirmed that the histological status of AX and IM
can provide important prognostic information in breast
cancer patients. Therefore, it was concluded that AX dissec-
tion and biopsy of IM are important in the detection of
regional lymph node metastases (Fentiman et al., 1991;
Noguchi et al., 1991).
We express our thanks to R. Yashiki and N. Takamura for their
excellent technical assistance.
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